Related Experiment Video
Updated: May 8, 2026

Isolation of Fidelity Variants of RNA Viruses and Characterization of Virus Mutation Frequency
Published on: June 16, 2011
Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis
Ana M Ortega-Prieto1, Julie Sheldon, Ana Grande-Pérez
1Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Consejo Superior de Investigaciones Científicas (CSIC), Campus de Cantoblanco, Madrid, Spain.
Abstract:
Lethal mutagenesis, or virus extinction produced by enhanced mutation rates, is under investigation as an antiviral strategy that aims at counteracting the adaptive capacity of viral quasispecies, and avoiding selection of antiviral-escape mutants. To explore lethal mutagenesis of hepatitis C virus (HCV), it is important to establish whether ribavirin, the purine nucleoside analogue used in anti-HCV therapy, acts as a mutagenic agent during virus replication in cell culture. Here we report the effect of ribavirin during serial passages of HCV in human hepatoma Huh-7.5 cells, regarding viral progeny production and complexity of mutant spectra. Ribavirin produced an increase of mutant spectrum complexity and of the transition types associated with ribavirin mutagenesis, resulting in HCV extinction. Ribavirin-mediated depletion of intracellular GTP was not the major contributory factor to mutagenesis since mycophenolic acid evoked a similar decrease in GTP without an increase in mutant spectrum complexity. The intracellular concentration of the other nucleoside-triphosphates was elevated as a result of ribavirin treatment. Mycophenolic acid extinguished HCV without an intervening mutagenic activity. Ribavirin-mediated, but not mycophenolic acid-mediated, extinction of HCV occurred via a decrease of specific infectivity, a feature typical of lethal mutagenesis. We discuss some possibilities to explain disparate results on ribavirin mutagenesis of HCV.
Insights
Ribavirin induces lethal mutagenesis, increasing mutations and extinguishing hepatitis C virus (HCV) in cell culture. This antiviral strategy counteracts viral adaptation by enhancing mutation rates, unlike mycophenolic acid which also inhibits HCV without mutagenesis.
Area of Science:
- Virology
- Antiviral Therapy
- Molecular Biology
Background:
- Lethal mutagenesis is an antiviral strategy to prevent viral escape mutants by increasing mutation rates.
- Hepatitis C virus (HCV) poses a significant global health challenge, necessitating novel therapeutic approaches.
- Ribavirin, a purine nucleoside analogue, is used in HCV therapy, but its mutagenic potential requires investigation.
Purpose of the Study:
- To determine if ribavirin acts as a mutagenic agent during HCV replication in cell culture.
- To investigate the mechanism of ribavirin-induced HCV extinction.
- To compare ribavirin's mutagenic effects with mycophenolic acid.
Main Methods:
- Serial passages of HCV in human hepatoma Huh-7.5 cells.
- Analysis of viral progeny production and mutant spectrum complexity.
- Measurement of intracellular nucleoside-triphosphate concentrations, including GTP.
Main Results:
- Ribavirin increased mutant spectrum complexity and specific transition types, leading to HCV extinction.
- Ribavirin-mediated HCV extinction involved a decrease in specific infectivity, characteristic of lethal mutagenesis.
- Mycophenolic acid extinguished HCV without increasing mutation complexity, despite similar GTP depletion.
Conclusions:
- Ribavirin functions as a mutagenic agent against HCV, inducing lethal mutagenesis and viral extinction.
- The mutagenic activity of ribavirin is distinct from its effect on intracellular GTP levels.
- Lethal mutagenesis represents a promising antiviral strategy for combating HCV.
Related Concept Videos
Hepatitis
Viral Mutations
Retrovirus Life Cycles
Viral Hepatitis I: Introduction
In vitro Mutagenesis
Mutations in Microorganisms

